Tag : T2DM
Psoriasis is a chronic inflammatory disorder characterized by systemic inflammation and elevated circulating levels of pro-inflammatory cytokines. This persistent inflammatory state has been implicated in immune-mediated injury across multiple organ systems, with particular involvement of renal tissues. However, few large-scale studies have evaluated whether psoriasis independently increases the risk of renal complications in type 2 diabetes mellitus (T2DM) patients receiving guideline-directed renoprotective therapies. A retrospective cohort study was performed by researchers in Texas to compare the risk of diabetic nephropathy, chronic kidney disease (CKD), end-stage renal disease (ESRD), and dialysis in T2DM patients with and without psoriasis who were receiving angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB) or sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapies.
Type 2 diabetes mellitus (T2DM) has long been associated with an increased risk of liver-related complications, including hepatic decompensation, hepatocellular carcinoma, and liver-related mortality. While elevated glycated hemoglobin A1c (HbA1c) levels are a known risk factor, the influence of HbA1c trajectories over time on liver outcomes remains poorly understood. To address this, a territory-wide cohort study was conducted in Hong Kong to evaluate the impact of HbA1c trajectories on the development of liver-related complications in patients with T2DM.1 During the AASLD Annual Meeting 2024, Dr. Yip, Cheuk-Fung Terry from The Chinese University of Hong Kong, presented the study findings.
